 |
|
Emerging Pharmacotherapies for Creutzfeldt-Jakob Disease
Carsten Korth, MD;
Peter J. Peters, PhD
Arch Neurol. 2006;63:497-501.
Only a few years ago, pharmacotherapy of Creutzfeldt-Jakob disease was inconceivable. The enigmatic prion agent causing Creutzfeldt-Jakob disease, consisting solely of a misfolded conformational isoform, the scrapie prion protein, of the normal cellular prion protein was considered hard to treat by routine drug development. However, huge progress has been achieved in recent years, demonstrating principal reversibility of the neuropathological features and protection from clinical symptoms in animal models and introducing potential pharmaceutical agents. Among the most promising ones, antibodies have been shown to be protective against prion disease and heterocyclic small-molecule compounds have been proposed as antiprion lead compounds, initiating clinical trials.
Author Affiliations: Institute for Neuropathology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany (Dr Korth); and the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam (Dr Peters).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Doxorubicin and Congo Red Effectiveness on Prion Infectivity in Golden Syrian Hamster
CORATO et al.
Anticancer Res 2009;29:2507-2512.
ABSTRACT
| FULL TEXT
Opposing effects of ERK and p38-JNK MAP kinase pathways on formation of prions in GT1-1 cells
Nordstrom et al.
FASEB J. 2009;23:613-622.
ABSTRACT
| FULL TEXT
Voltage-Gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease
Geschwind et al.
Arch Neurol 2008;65:1341-1346.
ABSTRACT
| FULL TEXT
Systematic review of therapeutic interventions in human prion disease
Stewart et al.
Neurology 2008;70:1272-1281.
ABSTRACT
| FULL TEXT
|
